{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2020-04-27&hansardHeading=Orphan+Drugs", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-answer.dateOfAnswer=2020-04-27&hansardHeading=Orphan+Drugs", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2020-04-27&_metadata=all&hansardHeading=Orphan+Drugs", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2020-04-27&_page=0&hansardHeading=Orphan+Drugs", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2020-04-27&hansardHeading=Orphan+Drugs", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2020-04-27&hansardHeading=Orphan+Drugs", "items" : [{"_about" : "http://data.parliament.uk/resources/1365661", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1365661/answer", "answerText" : {"_value" : "<p>The attached table lists medicines with a European Medicines Agency orphan designation appraised by the National Institute for Health and Care Excellence through the single technology appraisal process and the category of recommendation made in each case.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4362", "label" : {"_value" : "Biography information for Edward Argar"}
        }
        , "answeringMemberConstituency" : {"_value" : "Charnwood"}
        , "answeringMemberPrinted" : {"_value" : "Edward Argar"}
        , "attachment" : {"_about" : "http://data.parliament.uk/resources/1365661/answer/attachment/1", "fileName" : {"_value" : "FORMATTED TABLE FOR MINISTERIAL CLEARANCE PQ68424 - EMA Orphan Meds Appraisal table  (1).docx"}
          , "title" : " EMA Orphan Meds Appraisal table "}
        , "dateOfAnswer" : {"_value" : "2021-11-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2021-11-10T16:31:43.857Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2021-11-02", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Orphan Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, which medicines with an EMA Orphan Medicines Product designation have been appraised by NICE through a Single Technology Appraisal process; and what category of recommendation, (a) recommended, (b) optimised, (c) Cancer Drugs Fund, (d) not recommended and (e) only in research, was made in each case.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4658", "label" : {"_value" : "Biography information for Alex Sobel"}
      }
      , "tablingMemberConstituency" : {"_value" : "Leeds North West"}
      , "tablingMemberPrinted" : [{"_value" : "Alex Sobel"}
      ], "uin" : "68424"}
    , {"_about" : "http://data.parliament.uk/resources/1186527", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1186527/answer", "answerText" : {"_value" : "<p>There are no current plans to establish a further National Institute for Health and Care Excellence (NICE) assessment programme for orphan medicines. Where companies are willing to price their drugs fairly in a way that reflects the benefits they bring to patients, NICE has been able to recommend a number of orphan medicines for routine NHS funding through its technology appraisal programme. NICE is reviewing its methods for the development of technology appraisal and highly specialised technology recommendations, including the methods for the assessment of medicines licensed for rare diseases. The creation of an Innovative Medicines Fund will also build on the success of the Cancer Drugs Fund and support access to the most advanced medicines for patients with rare diseases.<\/p><p> <\/p><p> <\/p><p> <\/p><p> <\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
        }
        , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
        , "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
        , "dateOfAnswer" : {"_value" : "2020-04-27", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2020-04-27T13:01:11.17Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2020-03-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Orphan Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of establishing a new orphan medicines pathway at NICE to enable orphan medicines which do not qualify for the highly specialised technology evaluation programme to be appraised.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/104", "label" : {"_value" : "Biography information for Crispin Blunt"}
      }
      , "tablingMemberConstituency" : {"_value" : "Reigate"}
      , "tablingMemberPrinted" : [{"_value" : "Crispin Blunt"}
      ], "uin" : "32035"}
    , {"_about" : "http://data.parliament.uk/resources/1186529", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1186529/answer", "answerText" : {"_value" : "<p>The National Institute for Health and Care Excellence (NICE) is responsible for the review of the methods it uses in the development of its technology appraisal and highly specialised technology recommendations in England. NICE has advised that additional factors and modifiers that may affect NICE\u2019s decisions, including factors relevant to orphan medicines and medicines that substantially improve health and/or life expectancy, are being considered within its methods review. This review will give consideration to approaches in other health technology assessment bodies, including the devolved administrations.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
        }
        , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
        , "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
        , "dateOfAnswer" : {"_value" : "2020-04-27", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2020-04-27T13:36:50.233Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2020-03-19", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Orphan Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he made of the effect of the (a) introduction of the ultra-orphan pathway by the Scottish Medicines Consortium and (b) additional factors and modifiers for orphan medicines and medicines that have evidence of achieving a substantial improvement in life expectancy and/or quality of life considered by the Scottish Medicines Consortium in relation to informing methods and processes at the National Institute for Health and Care Excellence.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/104", "label" : {"_value" : "Biography information for Crispin Blunt"}
      }
      , "tablingMemberConstituency" : {"_value" : "Reigate"}
      , "tablingMemberPrinted" : [{"_value" : "Crispin Blunt"}
      ], "uin" : "32036"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 3, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}